{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12"],"submitter":["Chen H"],"pubmed_abstract":["<h4>Background</h4>Early screening of clinically significant prostate cancer (csPCa) may offer opportunities in revolutionizing the survival benefits of this lethal disease. We sought to introduce a modified prostate health index density (mPHI) model using imaging indicators and to compare its diagnostic performance for early detection of occult onset csPCa within the prostate-specific antigen (PSA) gray zone with that of PHI and PHID.<h4>Methods and participation</h4>Between August 2020 and January 2022, a training cohort of 278 patients (total PSA 4.0-10.0 ng/ml) who were scheduled for a prostate biopsy were prospectively recruited. PHI and PHID were compared with mPHI (LDTRD×APD×TPV×PHI) for the diagnosis performance in identifying csPCa. Pathology outcomes from systematic prostate biop"],"journal":["Frontiers in oncology"],"pagination":["864111"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9021722"],"repository":["biostudies-literature"],"pubmed_title":["Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection."],"pmcid":["PMC9021722"],"pubmed_authors":["Qian Y","Shi B","Gu Z","Chen H","Qu F","Ding J","Wu Y","Zhou J","Yu Y"],"additional_accession":[]},"is_claimable":false,"name":"Modified Prostate Health Index Density Significantly Improves Clinically Significant Prostate Cancer (csPCa) Detection.","description":"<h4>Background</h4>Early screening of clinically significant prostate cancer (csPCa) may offer opportunities in revolutionizing the survival benefits of this lethal disease. We sought to introduce a modified prostate health index density (mPHI) model using imaging indicators and to compare its diagnostic performance for early detection of occult onset csPCa within the prostate-specific antigen (PSA) gray zone with that of PHI and PHID.<h4>Methods and participation</h4>Between August 2020 and January 2022, a training cohort of 278 patients (total PSA 4.0-10.0 ng/ml) who were scheduled for a prostate biopsy were prospectively recruited. PHI and PHID were compared with mPHI (LDTRD×APD×TPV×PHI) for the diagnosis performance in identifying csPCa. Pathology outcomes from systematic prostate biop","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-20T00:17:59.476Z","creation":"2025-02-19T01:53:47.969Z"},"accession":"S-EPMC9021722","cross_references":{"pubmed":["35463344"],"doi":["10.3389/fonc.2022.864111"]}}